Olema Pharmaceuticals (OLMA) Non-Current Assets (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Non-Current Assets data on file, last reported at $17.4 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $17.4 million, up 34.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $67.8 million (up 35.51% YoY), and the FY2025 annual result was $18.0 million, up 43.75% from the prior year.
• Non-Current Assets eased to $17.4 million in Q1 2026 per OLMA's latest filing, from $18.0 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $18.1 million in Q3 2025 and troughed at $6.1 million in Q2 2023.
• A 5-year average of $11.3 million and a median of $11.6 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets soared 595.37% in 2022, then dropped 19.26% in 2023.
• A 5-year view of Non-Current Assets shows it stood at $6.7 million in 2022, then soared by 54.64% to $10.4 million in 2023, then rose by 19.88% to $12.5 million in 2024, then surged by 43.75% to $18.0 million in 2025, then retreated by 3.13% to $17.4 million in 2026.
• Business Quant data shows OLMA's Non-Current Assets at $17.4 million in Q1 2026, $18.0 million in Q4 2025, and $18.1 million in Q3 2025.